Jasper Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

• Jasper Therapeutics Inc JSPR.OQ reported a quarterly adjusted loss of $1.62​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of $-1.50. The mean expectation of eleven analysts for the quarter was for a loss of $1.23 per share. Wall Street expected results to range from $-1.41 to -100 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Jasper Therapeutics Inc's reported EPS for the quarter was a loss of $1.62​.

• The company reported a quarterly loss of $24.32 million.

• Jasper Therapeutics Inc shares had fallen by 72.3% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 0.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Jasper Therapeutics Inc is $64.00

This summary was machine generated from LSEG data March 3 at 02:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)